Clinical Trial

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

Study acronym: CLEAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of lesigercept in approximately 150 participants with CSU. By enrolling participants with an inadequate response to H1-antihistamines, including those previously treated with omalizumab, this study is expected to provide evidence for the clinical utility of lesigercept and to further characterize its benefit-risk profile in the target participant population.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-14
critical Primary endpoint(s) modified 2026-04-14
Trial Details
NCT Number NCT07415551
Lead Sponsor Yuhan Corporation
Conditions Allergic Diseases, Chronic Spontaneous Urticaria (CSU)
Enrollment 150 participants
Start Date 2026-03-26
Primary Completion 2027-06-19 (estimated)
Study Completion 2027-07-24 (estimated)
Updated on ClinicalTrials.gov 2026-04-15